Latigo Biotherapeutics raises $397m IPO to fund non-opioid pain pipeline
Latigo Biotherapeutics completed an upsized initial public offering in August 2026, raising gross proceeds of $397.4 million including the full exercise of the underwriters' over-allotment option. Combined with existing cash, the Nasdaq-listed company said the proceeds are expected to fund operations into 2029, providing a runway its management describes as sufficient to carry multiple clinical programmes through key readouts.
The IPO headline coincided with a notable scientific moment: The New England Journal of Medicine published positive clinical results for onzotrigine, Latigo's lead candidate and an oral inhibitor of the NaV 1.8 sodium ion channel. The abdominoplasty trial met its primary endpoint, the Summed Pain Intensity Difference over 48 hours, with high statistical significance versus placebo. The company said the drug demonstrated rapid onset, favourable tolerability and opioid-sparing potential. Latigo noted that this is only the second original research paper in NEJM reporting clinical results for a novel acute pain drug in the past 15 years, a characterisation that underscores the relatively thin recent pipeline in non-opioid analgesics.
Phase 3 and pipeline progress
Latigo plans to initiate two Phase 3 studies for onzotrigine in the second half of 2026: a randomised, double-blind, placebo-controlled bunionectomy trial in patients with moderate-to-severe acute pain, and a single-arm open-label safety study. Topline results from both are anticipated in the second half of 2027. The company has also completed bioavailability studies for an intravenous formulation of onzotrigine, with preliminary data indicating approximately 100% oral bioavailability, a finding that could simplify clinical logistics and broaden the drug's utility in perioperative settings.
For chronic pain, Latigo has initiated a Phase 2 crossover trial of LTG-321, a structurally related NaV 1.8 inhibitor, in approximately 120 patients with knee osteoarthritis. The trial is running across multiple sites in Denmark, with enrolment underway and topline results expected in the second half of 2027. A third candidate, LTG-418, has cleared 14-day non-GLP toxicology studies in rats and non-human primates, positioning it for further preclinical work. LTG-418 is designed for low-dose administration, which the company says could enable delivery routes beyond oral and intravenous.
Market context and regulatory backdrop
The non-opioid analgesic space has attracted renewed commercial and regulatory interest following years of under-investment. The US opioid crisis has prompted the FDA to issue specific guidance on the development of non-opioid analgesics for both acute and chronic pain, and the agency has signalled a willingness to engage early with sponsors working in the category. Latigo's new senior vice president of global regulatory affairs, Naomi Lowy, spent 18 years at the FDA, latterly as deputy director of the Division of Anesthesia, Addiction Medicine, and Pain Medicine, where she had signatory authority over analgesic New Drug Applications and co-authored the relevant FDA guidance documents. Her appointment gives Latigo an unusually direct line into the regulatory thinking that will shape onzotrigine's path to approval.
Several other companies are pursuing NaV 1.8 and related sodium channel targets for pain, meaning the competitive landscape will sharpen as programmes advance into Phase 3. Investors will be watching the 2027 readout windows closely: positive bunionectomy data would substantially de-risk onzotrigine's commercial case and set the stage for an NDA filing. Q2 2026 financials showed an operating loss of $25.8 million on R&D spend of $21.2 million, broadly flat year-on-year on the research line, suggesting disciplined capital deployment ahead of a capital-intensive Phase 3 cycle.